(Q44512468)

English

Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

5

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Jorge Eduardo Cortes

2

object named as

Jorge Cortes

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Apostolia Maria Tsimberidou

3

object named as

Apostolia Tsimberidou

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

4

object named as

Elihu Estey

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Francis J Giles

6

object named as

Francis J Giles

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Efrosyni Apostolidou

1

object named as

Efrosyni Apostolidou

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 October 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Leukemia Research

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

887-891

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of liposomal daunorubicin in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Veno-occlusive disease of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

CD33 as a target for selective ablation of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg).

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0145-2126(03)00021-3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44512468&oldid=2070300728"